Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ciccarese, C; Büttner, T; Cerbone, L; Zampiva, I; Monteiro, FSM; Basso, U; Pichler, M; Vitale, MG; Fiala, O; Roviello, G; Kopp, RM; Carrozza, F; Pichler, R; Grillone, F; Calabuig, EP; Zeppellini, A; Küronya, Z; Galli, L; Facchini, G; Sunela, K; Mosca, A; Molina-Cerrillo, J; Spinelli, GP; Ansari, J; Scala, A; Mollica, V; Grande, E; Buti, S; Kanesvaran, R; Zakopoulou, R; Bamias, A; Rizzo, M; Massari, F; Iacovelli, R; Santoni, M.
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
Int J Cancer. 2024;
Doi: 10.1002/ijc.35141
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real-world data confirming the adequate first-line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO-based combinations within the ARON-1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non-sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first-line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non-sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6-44.2) in sRCC and 35.3 months (95%CI 30.2-40.4) in non-sRCC patients (p = .013). The median progression-free survival (PFS) was longer in non-sRCC patients compared to sRCC (14.5 vs. 12.3 months, p = .064). In patients treated with first-line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO (p = .729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO (p = .606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO-based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted.
- Find related publications in this database (Keywords)
- ARON-1 study
- immune-based combinations
- immunotherapy
- NCT05287464
- renal cell carcinoma
- sarcomatoid differentiation
- survival